Novartis Stock - Weekly review and pharma sector comparison
19.06.2026 - 14:39:50 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 14:38 CET. Details in the imprint.
Novartis (CH0012005267) is ending the week with a relatively steady stock profile while investors reassess big pharma after recent earnings and patent headlines. The Swiss group stays in focus as a large-cap defensive name with sizable late-stage assets.
All news and background on Novartis stock
Key figures, company announcements and additional market coverage on Novartis can be found in the dedicated topic hub.
How Novartis performed this week
Novartis shares have traded in a narrow range this week on the SIX Swiss Exchange, reflecting a broader pause across European large-cap pharma after the latest round of first-quarter results earlier in the season.
According to exchange data, the stock remains close to its recent 52-week highs, underpinning the company’s role as a core holding in the Swiss Market Index and the Stoxx Europe 50.
Peer comparison in big pharma
In the wider sector, several European peers have faced more acute pressure from patent cliffs and weaker product cycles, leading to softer share performances compared with Novartis over recent months.
A recent analysis of heart-failure drug Entresto highlighted how patent erosion and generic competition can weigh on revenue growth, a theme investors apply across the sector when valuing mature blockbusters.
The product behind the stock
Novartis generates most of its revenue from patented prescription medicines, including cardiovascular therapy Entresto and immunology and oncology drugs, complemented by a broad late-stage pipeline in areas such as hematology and ophthalmology.
Where the stock trades today
The shares of Novartis (CH0012005267) trade on SIX Swiss Exchange at CHF 126.60 as of 06/19/2026, 14:30 CET.
Key facts on Novartis stock
- Company: Novartis AG
- ISIN: CH0012005267
- WKN: 904278
- Ticker: NOVN
- Venue: SIX Swiss Exchange
- Price (as of 06/19/2026, 14:30 CET): 126.60 CHF
- Market cap: 265,000,000,000 CHF (as of 06/19/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI, Stoxx Europe 50, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
